1 Muhammad Ali, 2 Fazal Mohammad, 3 Nadia Niaz, 4 Khurram Ali, 5 Iqbal Lodhi
1 Hamdard University Karachi.
2Baluchistan Institute of Nephro Urology Quetta
3Baluchistan Institute of Nephro Urology Quetta
4PIMS
5UHS
Correspondence: Muhammad Ali, Hamdard University Karachi
Abstract
Background: Polycystic Kidney Disease (PKD) is a genetic disorder characterized by the progressive development of kidney cysts, leading to renal impairment and potentially end-stage renal disease. Traditional management strategies have focused on controlling symptoms and delaying disease progression. Recent advancements have introduced novel therapeutic options, including tolvaptan, a vasopressin V2 receptor antagonist, and other emerging interventions.
Aim: This study aimed to evaluate the efficacy and safety of current and emerging therapies for PKD, with a particular focus on tolvaptan and other novel treatments, to provide a comprehensive overview of their impact on disease progression and patient outcomes.
Methods: A total of 120 patients with a diagnosis of PKD participated in this study, which spanned from May 2023 to April 2024. The study employed a comparative approach, analysing the outcomes of patients receiving tolvaptan versus those undergoing novel interventions. Data were collected through clinical assessments, imaging studies, and laboratory tests to monitor disease progression, renal function, and adverse effects.
Results: The study revealed that tolvaptan significantly reduced the rate of kidney enlargement and deterioration of renal function compared to conventional treatments. Novel therapies, including those targeting cyst growth and fibrosis, also demonstrated promising results in slowing disease progression and improving renal outcomes. Adverse effects were generally manageable, with no major safety concerns identified.
Conclusion: Tolvaptan and other emerging therapies have shown substantial potential in managing PKD, offering new hope for patients with this challenging condition. These treatments have been effective in slowing disease progression and improving patient outcomes, although further research is needed to optimize their use and evaluate long-term effects.
Keywords: Polycystic Kidney Disease, Tolvaptan, Novel Therapies, Disease Progression, Renal Function, Emerging Interventions